Kong J, Miao W, Lu J, Liu Y, et al. Shorter duration of Blinatumomab administration to 14 days has same efficacy and safety profile in treatment of relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A retrospective single-center study. Acta Haematol 2024 Oct 28:1-10. doi: 10.1159/000542060.
PMID: 39467525